Aprepitant for erlotinib-induced pruritus.
Dominique
D
Levêque
D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D019540:Area Under Curve; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004334:Drug Administration Schedule; D004347:Drug Interactions; D000069347:Erlotinib Hydrochloride; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D064729:Neurokinin-1 Receptor Antagonists; D056687:Off-Label Use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D011537:Pruritus / Q000139:chemically induced / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects / Q000493:pharmacokinetics*
D000970:Antineoplastic Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077608:Aprepitant; D000069347:Erlotinib Hydrochloride; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human